Contact us   Site map   Create an account
 
Search
   
 

Antibody Engineering and Directed Molecular Evolution

MilleGen is a french biotech company focused on Directed Molecular Evolution (DME) and genetic engineering of therapeutic antibodies. MilleGen has developed and patented a powerful DME method (MutaGen™) to generate molecular diversity which can be applied to any protein-based products. MutaGen™ protein optimisation technology occupies the heart of an efficient platform dedicated to antibody discovery. MilleGen's innovative platform, MutaGen™, combines random mutagenesis with a high throughput screening process and a bioinformatics analysis to improve human antibodies for therapeutic and diagnostic use. This platform allows selection of antibody candidates, their optimisation and their production as whole human antibody molecules which are ready to enter into clinical development.

Custom Services
MilleGen provides a know-how experience and expertise to research and industrial customers. The company offers an array of outsourcing options including High-Throughput DNA Sequencing, Bioinformatics, Gene cloning and Vector Development Services, Peptides Synthesis and Antibodies Engineering & Production.


>Quick access to products & services


About MilleGen | Legal Notices

Designed by Orealys
 

Latest News    

MilleGen is pleased to announce the successful evaluation by the Juvenile Diabetes Research Foundation (JDRF) to engineer an antibody which targets insulin secreting functional human beta cells.
Access to all news
 



MilleGen announces the successful evaluation by the "Pôle de compétitivité Cancer Bio Santé de Toulouse" of a project entitled "humanization of an antimetastatic murine monoclonal antibody". The project is in collaboration with a laboratory of INSERM in Lyon (France).
Access to all news 


MilleGen will attend several major conferences.
Read the Events and Conferences


MilleGen scientific publications.
Access to scientific publications